Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third-Quarter Global Net Revenues...Read more
Delivered quarterly revenue of $21.5 million in Q3, representing 5% YoY growth. Reduced quarterly cash burn to $3.9 million, a new record low for quarterly cash usage. Reaffirmed full year revenue guidance and narrowed adjusted EBITDA guidance. BURLINGTON, Mass. & NEW YORK / Oct 31, 2025 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with portable,...Read more
Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Preparing to submit Investigational New Drug applications for the treatment of psoriasis with CYPS317 and the treatment of multiple sclerosis with CYMS101 HOUSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG)...Read more
Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study Cash burn of $4.2 million in Q3 remains in line with projected quarterly range Ongoing engagement with FDA for supervisory appeal of the VenoValve PMA decision with feedback expected by the end of 2025 IRVINE, CA / ACCESS Newswire / October 31, 2025 / enVVeno Medical Corporation...Read more
Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range...Read more
Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 3% KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8% WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and Excluding the Impact of Foreign Exchange CAPVAXIVE Sales Were $244 Million GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7...Read more
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sales Increased 6% Year-Over-Year to $3.7 billion FOSTER CITY, Calif. / Oct 30, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. “We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and...Read more
Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billion Organic net sales increased 9.5% Reported operating income margin of 18.7% Adjusted operating income margin(1) increased 90 bps to 25.6% Reported EPS increased 2.8% to $2.22 Adjusted EPS(1) increased 11.1% to...Read more
PRINCETON, N.J. / Oct 30, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results. Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed third quarter 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025, which is...Read more
Total revenues for the third quarter 2025 increased 10% to $69.7 billion Shareholders' net income for the third quarter 2025 was $1.9 billion, or $6.98 per share Adjusted income from operations1 for the third quarter 2025 was $2.1 billion, or $7.83 per share Reaffirms 2025 outlook for adjusted income from operations1,2 of at least $29.60 per share2 The Cigna Group announced a new rebate-free pharmacy benefit model designed to lower...Read more
Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) Continued Broad Access and Balanced Utilization of AMVUTTRA Across All ATTR-CM Patient Segments Presented New Data from the HELIOS-B Phase 3 Study at Major Congresses Demonstrating Vutrisiran's Long-Term Cardiovascular Benefit and Lower...Read more
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET - Amsterdam, the Netherlands –...Read more
IRVINE, Calif. / Oct 30, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of...Read more
Revenue increased 22% to $64 billion GAAP1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88 Non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments; non-GAAP diluted EPS increased 36% to $2.55 Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $9.65 to $9.85 and fiscal year 2026 non-GAAP...Read more
First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic Erosion of VYVANSE® and FX Headwind Core Operating Profit Declined 8.8% at CER in the First Half, Reflecting Revenue Performance and Product Mix; Impact Partially Offset by Operational Efficiencies First Half Reported Operating Profit (-27.7% at AER) Impacted by Impairment Losses Incurred in Q2 OSAKA, Japan /...Read more
BRINSUPRI™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Japan BRINSUPRI Total Revenue of $28.1 Million for the Third Quarter of 2025 ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $114.3 Million for the Third Quarter of 2025, Reflecting 22% Growth Over the Third Quarter of...Read more
Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from operations up 19% Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55 Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be...Read more
SAN DIEGO / Oct 30, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a...Read more
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025 GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025 Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025 Repurchased 1.2 million shares of our common stock for $120 million at an average...Read more
Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company’s focus to drive continuous improvement and...Read more
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC by year-end 2025 Strong financial position with operating runway anticipated into 2028 CAMBRIDGE, Mass., Oct. 30, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on...Read more
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024 Gross margin of 71.1%, a...Read more
Highlights† Reported revenue of $384.2 million, up 13.0% Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectively GAAP operating margin of 11.1%, compared to 11.0% in prior year period Non-GAAP operating margin* of 19.7%, compared to 19.2% in prior year period GAAP EPS $0.46, down 3.0% Non-GAAP EPS* $0.92, up 6.7% Free cash flow* generation of $141.6 million over first nine months of...Read more
BANNOCKBURN, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (Year-over-year comparisons unless otherwise noted) Net revenue of $1,435.0 million, up...Read more
Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 Updated 2025 Full Year Guidance BRIDGEWATER, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2025. “Amneal delivered...Read more
Reports Q3 revenue of $993.7 million, up 43.5% year-over-year Beats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDA Has 100% of members in plans rated 4 stars or higher for second consecutive year in 2026, including two 5-star contracts in Nevada and North Carolina and a 4.5-star contract in Texas ORANGE, Calif., Oct. 30, 2025...Read more
U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including U.S. net product sales of $113.2 million Retired remaining $69 million of 2025 convertible notes and achieved $40 million EU market access milestone, further strengthening financial foundation 2025 KDIGO guidelines and streamlined REMS...Read more
Total revenue grew $46 million or 30% to $197 million Surgical revenue grew 31% to $177 million Full-year revenue and profitability guidance increased CARLSBAD, Calif. / Oct 30, 2025 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2025, and recent...Read more
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN Reported EMPAVELI U.S. net product revenue of $27 million, reflecting strong early launch in C3G and primary IC-MPGN and continued high patient compliance in PNH SYFOVRE® (pegcetacoplan injection) total injection...Read more
$12.9 million in third quarter PYRUKYND® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026 RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026 Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results...Read more
MECHANICSBURG, Pa., Oct. 30, 2025 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its third quarter ended September 30, 2025, and the declaration of a cash dividend. For the third quarter ended September 30, 2025, revenue increased 7.2% to $1,363.4 million, compared to $1,271.6 million for the same quarter, prior year. Income from continuing...Read more
Omnicell delivers strong third quarter financial results Results exceed previously issued third quarter 2025 guidance on all metrics Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas / Oct 30, 2025 / Business Wire / Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today...Read more
Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH® Q3 revenue of $27.4 million, up 9% compared to Q2 2025 Company announces pipeline program for next-generation NHE3 inhibitor; Potential application across multiple therapeutic areas Conference call...Read more
Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application for Tumor Treating Fields therapy use in pancreatic cancer submitted and under substantive review by the U.S. Food and Drug Administration BAAR, Switzerland / Oct 30, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that...Read more
Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026 Management to host conference call today, October 30, 2025, at 8:00 a.m....Read more
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year. Third quarter GAAP earnings per...Read more
3Q 2025 Total revenue grew 25% year-over-year to $59.4 million driven by 42% year-over-year growth in Payor revenue 3Q 2025 Net income of $3.3 million and adjusted EBITDA¹ of $5.0 million 3Q 2025 Share repurchases of $8.8 million NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Talkspace, Inc. (“Talkspace” or the “Company”) (NASDAQ: TALK), today reported third quarter 2025 financial results. Three Months...Read more
Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership team with appointments to Board of Directors and Research and Innovation Advisory Board Cash and cash equivalents of $648.3 million as of September 30, 2025, excluding $38.2 million U.K. R&D tax credit received in October 2025; expected...Read more
Signed Definitive Agreement for the Sale of Products & Healthcare Services Segment Transaction Positions the Company as a Pure-Play Home-Based Care Business RICHMOND, Va. / Oct 30, 2025 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the third quarter ended September 30, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent...Read more
Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 Initiation of a global Phase 2 clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) in the fourth quarter of 2025 Projected cash runway extended to fund planned operations through 2028 SAN DIEGO / Oct 30, 2025 / Business Wire / Contineum Therapeutics, Inc....Read more
IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program to be presented at TRP in November; additional programs planned for 2026, including MP0726 targeting mesothelin. Updated data from Phase 1/2a trial of MP0533, a multispecific T cell engager for...Read more
IRVINE, CA / ACCESS Newswire / October 30, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 first quarter ended September 30, 2025. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2026 with the Securities and Exchange Commission today. Quarter Ended September 30, 2025 Net sales for the three months ended September 30, 2025, increased $3.6 million, or...Read more
US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system...Read more
Company to Host Conference Call Today, October 30, at 4:30pm ET BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business...Read more
Financial Highlights Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior year Third quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit Third quarter Adjusted EPS of $1.60 Generated year-to-date cash flow from operations of $7.2 billion Operational Highlights Aetna® receives...Read more
Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was...Read more
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Oct 29, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso® and Orenitram®. Total revenues in the third quarter of 2025 grew seven percent year-over-year to $799.5 million,...Read more
GAAP Diluted Loss Per Share of $(13.50); Adjusted Diluted Earnings Per Share of $0.50 Adjusted diluted EPS of $0.50 in the third quarter of 2025, including a $0.10 benefit of a low adjusted effective tax rate in the quarter as compared to the expected full year adjusted effective tax rate of 20-21%. $6.7 billion non-cash goodwill impairment, resulting in a GAAP loss and corresponding reduction of retained earnings in the third quarter...Read more
$120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment Attruby...Read more
TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 DAWNZERA™ (donidalorsen) launch off to encouraging start Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology...Read more
Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% PALO ALTO, Calif. / Oct 29, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial...Read more
Increases full-year guidance BIRMINGHAM, Ala., Oct. 29, 2025 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the third quarter ended September 30, 2025. Summary results Growth Q3 2025 Q3...Read more
DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving...Read more
HERCULES, Calif. / Oct 29, 2025 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products,"...Read more
Q3 revenue growth of 12% year-over-year Q3 net income of $30.6 million and non-GAAP net income of $67.8 million Q3 net income margin of 11%; adjusted EBITDA margin of 42% Raising revenue and adjusted EBITDA guidance for 2025 LEHI, Utah and LOUISVILLE, Ky., Oct. 29, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the third quarter ended...Read more
Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance VAUGHAN, Ontario / Oct 29,...Read more
ALISO VIEJO, Calif. / Oct 29, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2025. Key highlights include: Record net sales of $133.5 million in Q3 2025 increased 38% year-over-year on a reported...Read more
ANDOVER, Mass., Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $143.8 million in the third quarter of 2025, a 32% increase compared to the third quarter...Read more
Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 million Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 million acquired In-Process Research & Development ("IPR&D") charge, up...Read more
Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third quarter and $25.1 million year to date MASON, Ohio / Oct 29, 2025 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in...Read more
NEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2025 (“Third Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2024 (“Third Quarter 2024”). Highlights Third Quarter 2025 revenue of $626.4 million, down 2%...Read more
Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Conference Call Today,...Read more
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This...Read more
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial...Read more
Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior year Third Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38% Raising the Full Year...Read more
Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2028 CAMBRIDGE, Mass., Oct. 29, 2025...Read more
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizing Targeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J., Oct. 29, 2025...Read more
Continued Managed Services Revenue Growth and Focused Expense Management Drives Net Income Levels Company Reaffirms 2025 Financial Guidance PLANO, Texas / Oct 29, 2025 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced results for the third quarter ended September 30, 2025. In addition, the Company’s Board of Directors declared a regular quarterly dividend of $0.3125 per...Read more
Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024 BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026 Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date of December 30, 2025 Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in Q4 2025 Vanda...Read more
Third Quarter 2025 Revenues of $113.2 Billion Grew 12% Year-Over-Year Third Quarter Earnings of $2.59 Per Share, Adjusted Earnings $2.92 Per Share Cash Flows from Operations were $5.9 Billion, or 2.3x Net Income Raises Full Year 2025 Earnings Outlook to at least $14.90 Per Share; Adjusted Earnings of at least $16.25 Per Share - / Oct 28, 2025 / Business Wire / UnitedHealth Group (NYSE: UNH) reported third quarter 2025 results,...Read more
Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D charge FDA...Read more
Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash...Read more
Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion Diluted EPS: $3.12 versus $2.00 Adjusted EPS: $4.18 versus $3.50 Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timing Adjusted EPS range of $16.15...Read more
Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi® (ruxolitinib) net product revenue of $791 million, an increase of 7% compared to the same period in 2024 Opzelura® (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million, including...Read more
Net income available to common shareholders in third quarter 2025 was $342 million, or $3.86 per diluted share Adjusted diluted earnings per share1 increased 26.3% to $3.70 in third quarter 2025 compared to $2.93 in third quarter 2024 Consolidated Adjusted EBITDA1 in third quarter 2025 increased 12.4% to $1.099 billion compared to third quarter 2024; Third quarter 2025 Adjusted EBITDA margin was 20.8% Third quarter 2025 Ambulatory Care...Read more
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth CRENESSITY® (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollment Start Forms SAN DIEGO, Oct. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced...Read more
Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises Orders increased sequentially and greater than 20% year-over-year Increasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life...Read more
CINCINNATI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest provider of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its third quarter ended September 30, 2025, versus the comparable prior-year period. Results for Quarter...Read more
LOUISVILLE, Ky., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2025, increased Revenue guidance, and reiterated Adjusted EBITDA1 guidance. Financial Highlights (note: all figures represent continuing...Read more
Third Quarter Revenues of $394.2 Million GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 Company Raises 2025 Financial Expectations DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused...Read more
Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume growth to 33% year-over-year Expanded adjusted gross margin to 74% and generated adjusted net income1 of $14.7 million for the third quarter 2025 Raised guidance to deliver between $425 and $428 million in revenue with between 53% to 55% full year growth in exome and genome...Read more
Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the treatment of atopic dermatitis in children down to 2 years of age in October Company provides initial 2026 full year net product sales guidance of $455–$470 million WESTLAKE VILLAGE,...Read more
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney cancer Multiple readouts from the ARC-20 study of casdatifan are expected in 2026, including additional analyses of the late-line monotherapy cohorts early in 2026, followed by more mature data from the casdatifan plus...Read more
ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth ARCALYST 2025 expected net product revenue raised to $670 - $675 million KPL-387 granted Orphan Drug Designation for the treatment of pericarditis Cash balance increased by $44.3 million in Q3 2025 to $352.1 million Conference call and webcast scheduled for 8:30 am ET today LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE)...Read more
Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA FORT MYERS, Fla. / Oct 28, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic...Read more
Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-year WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Recent...Read more
DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 Châtillon, France, October 28, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company (the "Company"), reported financial results for the third quarter of 2025. The quarterly and nine months unaudited financial...Read more
SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing...Read more
SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Accomplishments Revenue grew 2% year-over-year and rebounded 105% sequentially quarter-over-quarter to...Read more
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Third Quarter 2025 Financial Results & Key Metrics Net sales of $27.3 million, up 63% compared to $16.7 million in...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE